Sales of Merck’s Keytruda double in the first quarter; the FDA approves AstraZeneca’s immunotherapy; Lilly’s insulin is under investigation in two states
Five things for pharma marketers to know: Wednesday, April 26, 2017
GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling ‘illegal’ products
Five things for pharma marketers to know: Monday, April 3, 2017
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Five things for pharma marketers to know: Friday, March 24, 2017
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Five things for pharma marketers to know: Tuesday, March 7, 2017